MDMA, GHB and Ketamine Carry Real Dependence Risks

Dependence on club drugs forms through the same reward and stress pathways as any other substance, but the speed and character vary by drug. MDMA depletes serotonin over time, so someone who uses heavily across months finds it harder and harder to feel ordinary pleasure, connection, or calm without it. The crash after use gets longer and deeper, and the natural response, taking more to restore the feeling, accelerates the cycle.

GHB dependence can set in faster than people expect, especially when it is used daily to manage anxiety, sleep, or social discomfort. Because it acts on GABA receptors, the brain compensates by turning down its own inhibitory signalling, and removing GHB from that adapted system produces rebound excitability that in severe cases looks like alcohol withdrawal.

In a large share of presentations, club drug use sits on top of an unaddressed mental health condition. Anxiety, depression, and trauma are all common, and the drug is often a way of managing those states rather than purely a night out. This is why dual diagnosis treatment is a concurrent clinical priority for many people who present with club drug dependence, not an add-on after the addiction work is done. Treating the substance use without treating what sits underneath it is how people end up back where they started.

Ketamine addiction develops differently from GHB or alcohol dependence. It does not produce the classic physical withdrawal syndrome of the depressants, there is no seizure risk on stopping, and the acute phase, mostly anxiety, craving, insomnia, and perceptual disturbance, is not dangerous in the same way. As NIDA's overview of ketamine describes, its effects are dissociative rather than sedative, and that shapes both the dependence and the recovery. None of that means stopping is simple or that the dependence is mild.

In heavy long-term users the psychological dependence can be severe. The dissociative state ketamine produces, sometimes called a k-hole at high doses, becomes a way of managing emotional pain, intrusive thoughts, or interpersonal anxiety, and the brain learns to lean on it. Removing it brings the underlying distress back with none of the buffer, and that is often what brings people to treatment: not a dramatic physical crisis but the recognition that the drug has become their main way of coping.

The physical consequences of heavy ketamine use are real and progressive. Urinary tract damage, sometimes called ketamine cystitis, develops in a proportion of heavy users and in serious cases needs specialist urological care. For clients presenting with significant ketamine use, bladder and urinary health is a specific clinical concern that Jintara's Day 2 medical workup is structured to assess, which places ketamine alongside benzodiazepine-class sedatives as a substance where the physical effects need attention beyond the standard detox screen. That assessment is explained to the client as part of understanding their overall health, not presented as alarm.

A consistent feature of the presentations Jintara sees is club drug use alongside unprocessed trauma. It is not universal, but it is common enough to assume rather than treat as an exception. MDMA in particular is associated with settings where boundaries blur, and a proportion of people who develop MDMA dependence have experienced sexual assault or other traumatic events, sometimes before the use began and sometimes within the nightlife environment itself.

GHB has a documented history of non-consensual use in social settings, which means some people presenting with GHB dependence are also managing the after-effects of experiences they have not fully processed. Ketamine at higher doses produces dissociative states that can mirror the dissociation some people already carry from trauma. In these cases the substance use and the trauma are entangled rather than separate.

Denise O'Leary, Jintara's Clinical Director, holds a master's degree in counselling psychology and is one of a small number of EMDRIA-certified EMDR therapists in Thailand. EMDR is not assigned automatically to everyone, and for clients who do have the clinical runway to begin trauma work, trauma reprocessing runs as an individual track alongside group sessions. It is most relevant for clients staying eight weeks or longer and is introduced after medical stabilisation, so four-week clients may not reach the processing stage. The aim is never to force the trauma work early, but to make it available when the person is stable enough to use it.

The period after residential treatment is where recovery is tested, and for club drug presentations the challenge is specific. The social settings where the drug was used have not changed, the people connected to them are still there, and the situations that made the drug appealing, whether social anxiety, loneliness, the search for intensity, or unprocessed trauma, are the same ones the person returns to.

Jintara begins aftercare planning in the third and fourth weeks of the stay, while the person is still in the structured environment and before the return-to-life pressure arrives. That planning identifies support options in the person's home country, such as NA, CA, or SMART Recovery, maps the specific triggers most likely to be present, and in some cases sets up continued individual therapy with a therapist in their home city.

The relapse prevention work is not a document handed over at discharge. It is a set of tools the person has practised while still supervised, and the small community at Jintara, where clients know each other meaningfully within the first week, gives many their first experience of building connection without a club drug to smooth the way. The principles of relapse prevention planning apply across every substance, and the framework developed in the alcohol silo translates directly to club drug aftercare. What changes for club drug clients is the specific trigger map, not the underlying method.